Trisenox is a brand name of arsenic trioxide, approved by the FDA in the following formulation(s):
TRISENOX (arsenic trioxide - injectable; injection)
Manufacturer: CEPHALON
Approval date: September 25, 2000
Strength(s): 1MG/ML [RLD]
Has a generic version of Trisenox been approved?
No. There is currently no therapeutically equivalent version of Trisenox available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Trisenox. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
Patent 6,723,351
Issued: April 20, 2004
Inventor(s): Raymond P.; Warrell, Jr. & Pier Paolo; Pandolfi & Janice L.; Gabrilove
Assignee(s): Memorial Sloan-Kettering Cancer Center
The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.Patent expiration dates:
- November 10, 2018✓
- November 10, 2018
Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
Patent 6,855,339
Issued: February 15, 2005
Inventor(s): Warrell, Jr.; Raymond P. & Pandolfi; Pier Paolo & Gabrilove; Janice L.
Assignee(s): Memorial Sloan-Kettering Cancer Center
The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.Patent expiration dates:
- November 10, 2018✓
- November 10, 2018
Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
Patent 6,861,076
Issued: March 1, 2005
Inventor(s): Warrell, Jr.; Raymond P. & Pandolfi; Pier Paolo & Gabrilove; Janice L.
Assignee(s): Memorial Sloan-Kettering Cancer Center
The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.Patent expiration dates:
- November 10, 2018✓
- November 10, 2018
Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
Patent 6,884,439
Issued: April 26, 2005
Inventor(s): Warrell, Jr.; Raymond P. & Pandolfi; Pier Paolo & Gabrilove; Janice L.
Assignee(s): Memorial Sloan-Kettering Cancer Center
The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.Patent expiration dates:
- November 10, 2018✓
- November 10, 2018
Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
Patent 6,982,096
Issued: January 3, 2006
Inventor(s): Warrell, Jr.; Raymond P. & Pandolfi; Pier Paolo & Gabrilove; Janice L.
Assignee(s): Memorial Sloan-Kettering Cancer Center
The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.Patent expiration dates:
- November 10, 2018✓
- November 10, 2018
See also...
- Trisenox Consumer Information (Wolters Kluwer)
- Trisenox Consumer Information (Cerner Multum)
- Trisenox Advanced Consumer Information (Micromedex)
- Trisenox AHFS DI Monographs (ASHP)
- Arsenic Consumer Information (Wolters Kluwer)
- Arsenic trioxide Consumer Information (Cerner Multum)
- Arsenic trioxide Intravenous Advanced Consumer Information (Micromedex)
- Arsenic Trioxide AHFS DI Monographs (ASHP)
No comments:
Post a Comment